China Healthwise Holdings (HKSE:00348) Other Current Receivables: HK$9.82 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is China Healthwise Holdings Other Current Receivables?

China Healthwise Holdings HKSE:00348 +2.99% Other Current Receivables is HK$9.82 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

China Healthwise Holdings's Other Current Receivables for the quarter that ended in Dec. 2025 was HK$9.82 Mil.

China Healthwise Holdings's quarterly Other Current Receivables increased from Dec. 2024 (HK$11.15 Mil) to Jun. 2025 (HK$12.86 Mil) but then stayed the same from Jun. 2025 (HK$12.86 Mil) to Dec. 2025 (HK$9.82 Mil).

China Healthwise Holdings's annual Other Current Receivables declined from Dec. 2023 (HK$20.50 Mil) to Dec. 2024 (HK$11.15 Mil) and declined from Dec. 2024 (HK$11.15 Mil) to Dec. 2025 (HK$9.82 Mil).

China Healthwise Holdings Other Current Receivables Related Terms

China Healthwise Holdings Other Current Receivables Historical Data

* Premium members only.

The historical data trend for China Healthwise Holdings's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Healthwise Holdings Other Current Receivables Chart

China Healthwise Holdings Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.10 137.72 20.50 11.15 9.82

China Healthwise Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.81 11.15 12.86 9.82 11.43

China Healthwise Holdings Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of HK$9.82 Mil mean?
China Healthwise Holdings (HKSE:00348) has a Other Current Receivables of HK$9.82 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on China Healthwise Holdings and its competitors.
Is China Healthwise Holdings' Other Current Receivables too high?
China Healthwise Holdings' current Other Current Receivables is HK$9.82 Mil.
How does China Healthwise Holdings' Other Current Receivables compare to competitors?
China Healthwise Holdings' Other Current Receivables of HK$9.82 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Healthcare Providers & Services company?
A good Other Current Receivables depends on the Healthcare Providers & Services industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on China Healthwise Holdings and its competitors. China Healthwise Holdings's current Other Current Receivables is HK$9.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Healthwise Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Healthwise Holdings (HKSE:00348) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.06, compared to a current price of HK$0.07 — trading 15% above its estimated fair value. The current Other Current Receivables is HK$9.82 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For China Healthwise Holdings (HKSE:00348), the current Other Current Receivables is HK$9.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

China Healthwise Holdings Business Description

Address 168-200 Connaught Road Central, Unit 1209, Shun Tak Centre, West Tower, Hong Kong, HKG
China Healthwise Holdings Ltd is an investment holding company. It operates in three segments: Chinese health products, Money lending business, and investment in financial instruments. The majority of its revenue comes from trading in Chinese health products, which includes, pharmaceutical products, ginseng, and dried seafood products. The company's geographical segments are Hong Kong and the PRC, of which key revenue is derived from Hong Kong.